Thalidomide May Enhance Response Rate of Metastatic Colorectal Cancer to Irinotecan

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 10 No 9
Volume 10
Issue 9

LITTLE ROCK, Arkansas-The antiangiogenic properties of thalidomide (Thalomid) as well as its ability to inhibit tumor necrosis factor-alpha (TNF-alpha) suggest that thalidomide might be a useful addition to regimens for treating advanced cancers. Rangaswamy Govindarajan, MD, said that thalidomide may enhance the response rate of metastatic colorectal cancer to irinotecan (Camptosar) while also reducing irinotecan-related gastrointestinal toxicities. Dr. Govindarajan is assistant professor of medicine at the University of Arkansas for Medical Science in Little Rock, Arkansas.

LITTLE ROCK, Arkansas—The antiangiogenic properties of thalidomide (Thalomid) as well as its ability to inhibit tumor necrosis factor-alpha (TNF-alpha) suggest that thalidomide might be a useful addition to regimens for treating advanced cancers. Rangaswamy Govindarajan, MD, said that thalidomide may enhance the response rate of metastatic colorectal cancer to irinotecan (Camptosar) while also reducing irinotecan-related gastrointestinal toxicities. Dr. Govindarajan is assistant professor of medicine at the University of Arkansas for Medical Science in Little Rock, Arkansas.

In stage 2 colorectal cancer, recurrence risk is correlated to angiogenesis. This has been demonstrated both with microvessel counts and with expression of vascular endothelial growth factor (VEGF). Thalidomide also has a number of effects on immune function, including inhibiting TNF-alpha and stimulating CD8+ T-lymphocytes. "Thalidomide’s immune modulating properties may be more important than its antiangiogenic effects in cancer treatment," Dr. Govindarajan said.

Experimental Use

Dr. Govindarajan discussed experimental use of thalidomide to treat a patient with stage IV colon cancer who had developed liver metastases after resection and adjuvant therapy with the Mayo Clinic 5-fluorouracil/leucovorin regimen. After radiofrequency ablation of liver metastases and three cycles of floxuridine, the patient developed lung metastases and worsening of liver metastases. He was then treated with irinotecan (325 mg/m² IV q 21 d) and thalidomide (400 mg/d PO) for three cycles with marked resolution of pulmonary metastasis and a decrease in the size of liver metastases.

Three more cycles of treatment were given and produced remission with no evidence of disease on CT scan. This patient remained in remission for 6 months on thalidomide maintenance treatment (400 mg/d) then relapsed with brain metastases.

This experience inspired a pilot study of thalidomide and irinotecan in 11 patients. Dr. Govindarajan said that treatment produced 3 complete remissions (CR) lasting 6 to 15 months and one partial remission (PR) lasting 20 months. "Nausea, vomiting, and diarrhea were all significantly less than would be expected with irinotecan alone," he said.

GI Toxicities Reduced

This promising result was follow by a study of 18 patients with metastatic colon cancer who had disease progression on 5-FU-based regimens. Dr. Govindarajan said that patients are treated with irinotecan on the European infusion schedule of 350 mg/m² IV over 90 minutes q 21 d and thalidomide 400 mg/d at bedtime. Response was assessed after every third cycle with imaging and carcinoembryonic antigen (CEA) assay. Patients with CR receive two more cycles of irinotecan/thalidomide and continue thalidomide for 1 year.

Fourteen of 18 patients were evaluable at the time of this report. "There has been one complete remission, in addition to three partial remissions, six patients with stable disease, and four with disease progression," Dr. Govindarajan said.

Late grade-3 diarrhea occurred in two patients, including one who had stopped thalidomide for other reasons. Grade 3/4 nausea and vomiting were rare.

"The reduction in the GI toxicities compared to historical data is extremely impressive," Dr. Govindarajan said. "Thalidomide appears to decrease the gastrointestinal toxicities of irinotecan. It is well tolerated at 400 mg/d, and the response rate of metastatic colorectal cancer to irinotecan appears to be enhanced by thalidomide."

Related Videos
Data from a ctDNA analysis of the phase 3 INTRIGUE study indicate that KIT mutational status may be associated with response to certain Tyrosine kinase inhibitors in GIST, according to an expert from the Yale Cancer Center in New Haven, Massachusetts.
Future research into the management of unresectable hepatocellular carcinoma may involve combining local therapies with checkpoint inhibitors like durvalumab and tremelimumab, according to Ghassan K. Abou-Alda, MD.
Patients with unresectable hepatocellular carcinoma who have recurrent disease following surgery or locally advanced diseases who will likely progress on local therapy may have an opportunity to benefit from tremelimumab and durvalumab following its FDA approval, according to Ghassan K. Abou-Alfa, MD.
Ghassan K. Abou-Alfa, MD, discusses the importance of improving access to novel therapies and combinations for patients with hepatocellular carcinoma across the world.
Ghassan K. Abou-Alfa, MD, spoke about the recent approval of tremelimumab plus durvalumab for patients with unresectable hepatocellular carcinoma, based on results from the phase 3 HIMALAYA trial.
Howard A. Burris, MD, highlighted previous findings of the phase 3 TOPAZ-1 trial assessing durvalumab plus gemcitabine and cisplatin vs placebo plus gemcitabine and cisplatin in advanced biliary tract cancer and patient-reported outcomes (PRO)data that were presented at 2022 ASCO.
Shubham Pant, MD discusses key findings from a basket trial examining the use of erdafitinib in patients with gastrointestinal cancers.